The Pink Sheet reports that, “FDA’s initiative to influence the safe use of dugs will kick off in the new year.”
According to Dr. Janet Woodcock, “FDA does not control the health care system, so our improving the use of marketed drugs, to a great extent, is going to involve influence rather than control,” by partnering with the growing patient safety movement, she said. “The vast majority of harm from approved drugs comes from misuse, inappropriate use … failure to use, abuse and medical mix-ups. There is just carnage out there, and we know that.”
“Influence rather than control” is a savvy and sophisticated concept -- one that many of our elected members of Congress could learn from.
This new "Safe Use" initiative is the patient-facing sibling of the agency’s “Safety First” pharmacovigilance progam. But it's more than that -- it's the FDA reasserting ownership of safety from those who would use it only as a malllet of fear.
And it’s a potent double feature.
According to Dr. Janet Woodcock, “FDA does not control the health care system, so our improving the use of marketed drugs, to a great extent, is going to involve influence rather than control,” by partnering with the growing patient safety movement, she said. “The vast majority of harm from approved drugs comes from misuse, inappropriate use … failure to use, abuse and medical mix-ups. There is just carnage out there, and we know that.”
“Influence rather than control” is a savvy and sophisticated concept -- one that many of our elected members of Congress could learn from.
This new "Safe Use" initiative is the patient-facing sibling of the agency’s “Safety First” pharmacovigilance progam. But it's more than that -- it's the FDA reasserting ownership of safety from those who would use it only as a malllet of fear.
And it’s a potent double feature.
